Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long-Acting, Synthetic glucagon-like peptide-2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function
© 2024 VectivBio AG. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology..
Renal impairment is a common complication in patients with short bowel syndrome with intestinal failure (SBS-IF). Glucagon-like peptide-2 analogs, such as apraglutide, have been developed as a treatment option for SBS-IF. This study assessed the potential for apraglutide overexposure in individuals with severely impaired renal function versus healthy volunteers with normal renal function. In this phase 1, open-label, multicenter, nonrandomized, parallel-group study, a single dose of apraglutide 5 mg was administered subcutaneously to individuals with severely impaired renal function (<30 mL/min/1.73 m2 ) and healthy volunteers with normal renal function (≥90 mL/min/1.73 m2 ). Primary pharmacokinetic endpoints were maximum observed concentration (Cmax ) and exposure to apraglutide (area under the curve [AUC] from time 0 to infinity [AUCinf ], and AUC from time 0 to the last quantifiable concentration [AUClast ]). Each group comprised 8 individuals. Results show that patients with severe renal impairment do not have increased apraglutide exposure. Apraglutide achieved a lower Cmax and AUCinf in individuals with severe renal impairment versus those with normal renal function (Cmax = 36.9 vs 59.5 ng/L; AUCinf = 3100 vs 4470 h · ng/mL, respectively). The respective geometric mean ratios were 0.620 and 0.693 for Cmax and AUCinf , and the upper bound of their 90% confidence intervals were <2, indicating patients with severe renal impairment were not overexposed to apraglutide versus those with normal renal function. Adverse events were mild or moderate in severity. Apraglutide does not require dose reduction for any degree of renal impairment and could be used in a broader patient population of renally impaired patients without dose adjustment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of clinical pharmacology - (2024) vom: 11. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Greig, Gérard [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Apraglutide |
|---|
| Anmerkungen: |
Date Revised 11.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/jcph.2423 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369552458 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369552458 | ||
| 003 | DE-627 | ||
| 005 | 20240311233158.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcph.2423 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM369552458 | ||
| 035 | |a (NLM)38465515 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Greig, Gérard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long-Acting, Synthetic glucagon-like peptide-2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 VectivBio AG. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology. | ||
| 520 | |a Renal impairment is a common complication in patients with short bowel syndrome with intestinal failure (SBS-IF). Glucagon-like peptide-2 analogs, such as apraglutide, have been developed as a treatment option for SBS-IF. This study assessed the potential for apraglutide overexposure in individuals with severely impaired renal function versus healthy volunteers with normal renal function. In this phase 1, open-label, multicenter, nonrandomized, parallel-group study, a single dose of apraglutide 5 mg was administered subcutaneously to individuals with severely impaired renal function (<30 mL/min/1.73 m2 ) and healthy volunteers with normal renal function (≥90 mL/min/1.73 m2 ). Primary pharmacokinetic endpoints were maximum observed concentration (Cmax ) and exposure to apraglutide (area under the curve [AUC] from time 0 to infinity [AUCinf ], and AUC from time 0 to the last quantifiable concentration [AUClast ]). Each group comprised 8 individuals. Results show that patients with severe renal impairment do not have increased apraglutide exposure. Apraglutide achieved a lower Cmax and AUCinf in individuals with severe renal impairment versus those with normal renal function (Cmax = 36.9 vs 59.5 ng/L; AUCinf = 3100 vs 4470 h · ng/mL, respectively). The respective geometric mean ratios were 0.620 and 0.693 for Cmax and AUCinf , and the upper bound of their 90% confidence intervals were <2, indicating patients with severe renal impairment were not overexposed to apraglutide versus those with normal renal function. Adverse events were mild or moderate in severity. Apraglutide does not require dose reduction for any degree of renal impairment and could be used in a broader patient population of renally impaired patients without dose adjustment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a apraglutide | |
| 650 | 4 | |a drug exposure | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a renal impairment | |
| 650 | 4 | |a short bowel syndrome | |
| 700 | 1 | |a Youssef, Nader N |e verfasserin |4 aut | |
| 700 | 1 | |a Bolognani, Federico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical pharmacology |d 1973 |g (2024) vom: 11. März |w (DE-627)NLM000005576 |x 1552-4604 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcph.2423 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 03 | ||